A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on
to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.